伊立替康、顺铂、卡培他滨联合化疗治疗晚期食管癌的疗效观察

Clinical study of advanced esophageal carcinoma treated with the regimen of irinotecanpto,cisplatin and capecitabine

目的:观察伊立替康、顺铂、卡培他滨联合化疗对晚期食管癌的近期疗效及不良反应。方法:经临床明确诊断的晚期食管癌病人21例,接受伊立替康、顺铂、卡培他滨联合化疗,伊立替康180mg/m2,d1,顺铂20mg/m2,d1-d5,卡培他滨2000mg/(m2.d),分早、晚2次口服,d1-d14,3周为一周期,治疗两个周期评价疗效一次。结果:21例患者可评价客观疗效和不良反应。完全缓解(CR)1例,部分缓解(PR)9例,稳定(SD)4例,进展(PD)7例。客观效率(RR)47.6%,疾病控制率(DCR)66.7%,中位疾病进展时间(mTTP)5.8个月。主要不良反应为腹泻、中性粒细胞减少及恶心和呕吐。结论:伊立替康、顺铂、卡培他滨联合化疗对晚期食管癌的疗效较好,不良反应可以控制。

Objective：To investigate the clinical effects and side effect of the patients with advanced esophageal carcinoma with the regimen of irinotecanpto,cisplatin and capecitabine.Methods： Irinotecanpto plus cisplatin and capecitabine were administrated to 21 cases with esophageal carcinoma confirmed by histopathology.Irinotecanpto 180mg/m2 intravenous infusion in the first day,cisplatin 20mg/m2 intravenous infusion from day 1to day 5,Capecitabine2000mg/（m2·d）was given from day 1 to day 14 every three weeks.The efficacy was analyzed after two cycles.Results： The 21 patients were all evaluable for efficacy and safety.Among 21 evaluable cases,there were 1 case achieved CR,9 cases PR,4 cases SD and 7 cases PD.The objective response rate（RR）was 47.6%（10/21）and disease control rate（DCR）was 66.7%（14/21）.The median time to progress was 5.8 months.Diarrhea,neutropenia,nausea and vomitting was the main side effect.Conclusion： The irinotecanpto plus cisplatin and capecitabine regimen show good efficacy with mild toxicity in treatment of advanced esophageal carcinoma.